A randomized clinical trial of combinations of artesunate and azithromycin for treatment of uncomplicated Plasmodium falciparum malaria in Thailand.
Southeast Asian J Trop Med Public Health
;
2000 Dec; 31(4): 801-7
Article
in English
| IMSEAR
| ID: sea-33090
ABSTRACT
Recently, a combination of artesunate and mefloquine has proved effective, although is contraindicated in early pregnancy and young children. Azithromycin, a widely used antibiotic and has antimalarial effects, replace mefloquine as a new alternative antimalarial regimen. Two hundred and two uncomplicated falciparum malaria patients were randomly assigned to 1 of 3 regimens. Patients in group I (n = 68) received artesunate 200 mg once daily for 3 days, group II (n = 67) received artesunate 200 mg together with mefloquine 10 mg/kg on the first 2 days and artesunate 200 mg together with mefloquine 5 mg/kg on the third day, and group III (n = 67) received artesunate 200 mg together with azithromycin 50 mg once daily for 3 days. The 28 day cure rates were 44, 98 and 56%, respectively. The median time to recrudescence was significantly longer in group III. In conclusion, a combination of artesunate and azithromycin might be useful in treating children in whom bacterial and malarial infections may be concomitant. However, further work is required in order to enhance its clinical efficacy.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Sesquiterpenes
/
Thailand
/
Female
/
Humans
/
Male
/
Child
/
Adolescent
/
Treatment Outcome
/
Malaria, Falciparum
/
Azithromycin
Type of study:
Controlled clinical trial
Country/Region as subject:
Asia
Language:
English
Journal:
Southeast Asian J Trop Med Public Health
Year:
2000
Type:
Article
Similar
MEDLINE
...
LILACS
LIS